Jonathan Symonds Acquires 1,650 Shares of GSK (LON:GSK) Stock

GSK plc (LON:GSK) insider Jonathan Symonds purchased 1,650 shares of the company’s stock in a transaction dated Monday, December 22nd. The stock was acquired at an average price of GBX 1,810 per share, with a total value of £29,865.

GSK Trading Up 0.2%

Shares of LON:GSK opened at GBX 1,814.50 on Wednesday. The business’s 50 day simple moving average is GBX 1,765.38 and its 200 day simple moving average is GBX 1,569.60. GSK plc has a 1 year low of GBX 1,242.50 and a 1 year high of GBX 1,853.50. The company has a debt-to-equity ratio of 114.64, a current ratio of 0.81 and a quick ratio of 0.73. The company has a market capitalization of £73.26 billion, a P/E ratio of 13.64, a P/E/G ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK) last announced its quarterly earnings data on Wednesday, October 29th. The company reported GBX 55 earnings per share for the quarter. GSK had a return on equity of 18.08% and a net margin of 8.02%. On average, research analysts anticipate that GSK plc will post 175.980975 EPS for the current fiscal year.

Wall Street Analyst Weigh In

GSK has been the topic of several recent analyst reports. Jefferies Financial Group raised their target price on shares of GSK from GBX 2,000 to GBX 2,100 and gave the company a “buy” rating in a report on Monday, November 3rd. JPMorgan Chase & Co. increased their price target on shares of GSK from GBX 1,400 to GBX 1,500 and gave the stock an “underweight” rating in a research report on Friday, November 7th. Shore Capital reissued a “buy” rating and issued a GBX 2,100 price objective on shares of GSK in a research note on Monday, October 20th. Finally, Berenberg Bank boosted their price objective on shares of GSK from GBX 1,600 to GBX 1,660 and gave the company a “hold” rating in a research report on Monday, November 24th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of GBX 1,762.

GSK News Summary

Here are the key news stories impacting GSK this week:

• Positive Sentiment: GSK agreed to sell its U.S. Human Genome Sciences manufacturing unit to Samsung Biologics for roughly $280m — a near‑term cash inflow that can be used to pay down debt, fund R&D or support capital returns; the deal also removes an asset/operational burden from GSK’s footprint, which investors often view as portfolio simplification. Samsung Biologics Boosts U.S. Presence With $280M GSK Facility Deal
• Positive Sentiment: Insider purchases: directors Wendy Becker and Jonathan Symonds bought shares (441 and 1,650 shares at ~GBX 1,809–1,810), signalling management confidence and providing a small psychological and technical bid under the stock. Wendy Becker Acquires 441 Shares of GSK (LON:GSK) Stock
• Neutral Sentiment: The buyer, Samsung Biologics, gains its first U.S. production base — a strategic move for Samsung but largely a reallocation of manufacturing capacity rather than a change to GSK’s core commercial portfolio; impact on GSK cashflow is immediate, but operational effects are limited. Samsung Biologics buys GSK’s Human Genome Sciences unit to expand US biologics manufacturing
• Negative Sentiment: GSK reached a pricing agreement with the U.S. government to cut certain drug prices — this creates downside risk to future revenue and margins for any covered products; the long‑term impact depends on scope, which drugs are included and how broadly the terms apply. GSK strikes deal to cut drug prices with US government

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.